Zanamivir
- Generic Name
- Zanamivir
- Brand Names
- Relenza, Dectova
- Drug Type
- Small Molecule
- Chemical Formula
- C12H20N4O7
- CAS Number
- 139110-80-8
- Unique Ingredient Identifier
- L6O3XI777I
- Background
A guanido-neuraminic acid that is used to inhibit neuraminidase.
- Indication
For the prevention and treatment of influenza A and B.
- Associated Conditions
- Flu caused by Influenza
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
- Conditions
- Influenza, Human
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 626
- Registration Number
- NCT01231620
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Relenza® Sentinel Site Monitoring Program in Japan
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1575
- Registration Number
- NCT01199744
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 202
- Registration Number
- NCT01014988
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00989404
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
- Conditions
- Influenza
- Interventions
- Drug: placebo capsuleDrug: placebo for inhalation
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2010-09-22
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 390
- Registration Number
- NCT00980109
- Locations
- 🇹🇭
Hospital for Tropical Diseases, Bangkok, Thailand
🇹🇭Faculty of Medicine Siriraj Hospital, Bangkok, Bangkoknoi, Thailand
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
- Conditions
- Upper Respiratory Tract InfectionInfluenza
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 4
- Registration Number
- NCT00979667
- Locations
- 🇭🇰
Sai Ying Pun Jockey Club General Outpatient Clinic, Hong Kong, Hong Kong
🇨🇳Shau Kei Wan Jockey Club Clinic, Hong Kong, Hong Kong, China
🇭🇰Fanling Family Medicine Centre, Hong Kong, Hong Kong
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2010-03-19
- Target Recruit Count
- 17
- Registration Number
- NCT00921726
- Locations
- 🇹🇭
Mathidol University, Salaya, Thailand
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00867139
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Mount Sinai Hospital, Canada
- Target Recruit Count
- 64
- Registration Number
- NCT00784784
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.